135 related articles for article (PubMed ID: 31465740)
1. Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome.
Herrera A; Fredholm S; Cheng A; Mimitou EP; Seffens A; Bar-Natan M; Sun A; Latkowski JA; Willerslew-Olsen A; Buus TB; Gluud M; Krejsgaard T; Torres-Rusillo S; Bonefeld CM; Woetmann A; Geisler C; Geskin LJ; Ouyang Z; Smibert P; Ødum N; Koralov SB
J Invest Dermatol; 2020 Mar; 140(3):713-716. PubMed ID: 31465740
[No Abstract] [Full Text] [Related]
2. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
[TBL] [Abstract][Full Text] [Related]
3. SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in Sézary syndrome.
Li Y; Wang J; Yu M; Wang Y; Zhang H; Yin J; Li Z; Li T; Yan H; Li F; Wang X
Leuk Lymphoma; 2018 Oct; 59(10):2405-2413. PubMed ID: 29334836
[TBL] [Abstract][Full Text] [Related]
4. SATB1 in Malignant T Cells.
Fredholm S; Willerslev-Olsen A; Met Ö; Kubat L; Gluud M; Mathiasen SL; Friese C; Blümel E; Petersen DL; Hu T; Nastasi C; Lindahl LM; Buus TB; Krejsgaard T; Wasik MA; Kopp KL; Koralov SB; Persson JL; Bonefeld CM; Geisler C; Woetmann A; Iversen L; Becker JC; Ødum N
J Invest Dermatol; 2018 Aug; 138(8):1805-1815. PubMed ID: 29751003
[TBL] [Abstract][Full Text] [Related]
5. Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas.
Grzanka A; Grzanka D; Gagat M; Tadrowski T; Sokołowska-Wojdyło M; Marszałek A; Placek W
Pol J Pathol; 2012 Jun; 63(2):101-5. PubMed ID: 22864778
[TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
7. Increased Expression of PLS3 Correlates with Better Outcome in Sézary Syndrome.
Boonk SE; Zoutman WH; Putter H; Ram-Wolff C; Felcht M; Klemke CD; Ranki A; Quaglino P; Whittaker S; Bagot M; Willemze R; Vermeer MH
J Invest Dermatol; 2017 Mar; 137(3):754-757. PubMed ID: 27984038
[No Abstract] [Full Text] [Related]
8. Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12.
Suchin KR; Cassin M; Gottleib SL; Sood S; Cucchiara AJ; Vonderheid EC; Rook AH
J Am Acad Dermatol; 2001 Jan; 44(1):28-32. PubMed ID: 11148473
[TBL] [Abstract][Full Text] [Related]
9. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
10. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
[TBL] [Abstract][Full Text] [Related]
11. Aneuploid malignant T cells from a patient with Sézary syndrome can be visualized by in situ hybridization.
Hindkjaer J; Brandt CA; Kaltoft K
Arch Dermatol; 1993 Sep; 129(9):1141-5. PubMed ID: 8363397
[TBL] [Abstract][Full Text] [Related]
12. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.
Michel L; Jean-Louis F; Begue E; Bensussan A; Bagot M
Blood; 2013 Feb; 121(8):1477-8. PubMed ID: 23429988
[No Abstract] [Full Text] [Related]
13. Mycosis fungoides and the Sézary syndrome.
Gisselbrecht C; Dubertret L
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):73-5. PubMed ID: 8511044
[No Abstract] [Full Text] [Related]
14. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
[TBL] [Abstract][Full Text] [Related]
15. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the IL-31 pathway in Mycosis fungoides and Sézary syndrome.
Möbs M; Gryzik S; Haidar A; Humme D; Beyer M; Vandersee S
Arch Dermatol Res; 2015 Aug; 307(6):479-85. PubMed ID: 25488078
[TBL] [Abstract][Full Text] [Related]
17. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
[TBL] [Abstract][Full Text] [Related]
18. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
19. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
20. PD-1 Overexpression in Sézary Syndrome Is Epigenetically Regulated.
Najidh S; Zoutman WH; Schrader AMR; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2023 Dec; 143(12):2538-2541.e7. PubMed ID: 37270066
[No Abstract] [Full Text] [Related]
[Next] [New Search]
